Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2019 AND VI 37 AND IP 9
Results: 8
1
2
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
- Published in:
- 2019
- By:
- Publication type:
- journal article
3
Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
- Published in:
- 2019
- By:
- Publication type:
- journal article
4
Severity-Adjusted Probability of Being Cost Effective.
- Published in:
- 2019
- By:
- Publication type:
- journal article
5
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions.
- Published in:
- 2019
- By:
- Publication type:
- journal article
6
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article
7
Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample.
- Published in:
- 2019
- By:
- Publication type:
- journal article
8
Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article